<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38543718</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Feb</Month><Day>24</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Cordycepin Inhibits Enterovirus A71 Replication and Protects Host Cell from Virus-Induced Cytotoxicity through Adenosine Action Pathway.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">352</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16030352</ELocationID><Abstract><AbstractText>Enterovirus A71 (EV-A71) infection typically causes mild illnesses, such as hand-foot-and-mouth disease (HFMD), but occasionally leads to severe or fatal neurological complications in infants and young children. Currently, there is no specific antiviral treatment available for EV-A71 infection. Thus, the development of an effective anti-EV-A71 drug is required urgently. Cordycepin, a major bioactive compound found in <i>Cordyceps</i> fungus, has been reported to possess antiviral activity. However, its specific activity against EV-A71 is unknown. In this study, the potency and role of cordycepin treatment on EV-A71 infection were investigated. Results demonstrated that cordycepin treatment significantly reduced the viral load and viral ribonucleic acid (RNA) level in EV-A71-infected Vero cells. In addition, EV-A71-mediated cytotoxicity was significantly inhibited in the presence of cordycepin in a dose-dependent manner. The protective effect can also be extended to Caco-2 intestinal cells, as evidenced by the higher median tissue culture infectious dose (TCID<sub>50</sub>) values in the cordycepin-treated groups. Furthermore, cordycepin inhibited EV-A71 replication by acting on the adenosine pathway at the post-infection stage. Taken together, our findings reveal that cordycepin could be a potential antiviral candidate for the treatment of EV-A71 infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Yi-Ping</ForeName><Initials>YP</Initials><AffiliationInfo><Affiliation>Department of Cell Biology and Anatomy, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Chun-Keung</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Infectious Disease and Signaling Research, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Tak-Wah</ForeName><Initials>TW</Initials><Identifier Source="ORCID">0000-0002-0131-7339</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Applied Nanomedicine, National Cheng Kung University, Tainan 70101, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Li-Ching</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Department of Biological Science &amp; Technology, China Medical University, Taichung 406040, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Bu-Miin</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Department of Cell Biology and Anatomy, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Research, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NSTC 110-2320-B-006-025-MY3</GrantID><Agency>National Science and Technology Council, Taiwan</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>GZ8VF4M2J8</RegistryNumber><NameOfSubstance UI="C058120">cordycepin</NameOfSubstance></Chemical><Chemical><RegistryNumber>K72T3FS567</RegistryNumber><NameOfSubstance UI="D000241">Adenosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003839">Deoxyadenosines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000241" MajorTopicYN="N">Adenosine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018938" MajorTopicYN="N">Caco-2 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="Y">Hand, Foot and Mouth Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003839" MajorTopicYN="Y">Deoxyadenosines</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adenosine pathway</Keyword><Keyword MajorTopicYN="N">antiviral activity</Keyword><Keyword MajorTopicYN="N">cordycepin</Keyword><Keyword MajorTopicYN="N">enterovirus A71</Keyword><Keyword MajorTopicYN="N">infectious disease</Keyword><Keyword MajorTopicYN="N">traditional herbal medicine</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>28</Day><Hour>1</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38543718</ArticleId><ArticleId IdType="pmc">PMC10974990</ArticleId><ArticleId IdType="doi">10.3390/v16030352</ArticleId><ArticleId IdType="pii">v16030352</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nayak G., Bhuyan S.K., Bhuyan R., Sahu A., Kar D., Kuanar A. Global emergence of enterovirus 71: A systematic review. Beni. Suef Univ. J. Basic Appl. Sci. 2022;11:78. doi: 10.1186/s43088-022-00258-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43088-022-00258-4</ArticleId><ArticleId IdType="pmc">PMC9188855</ArticleId><ArticleId IdType="pubmed">35730010</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu K., Onintsoa Diarimalala R., Yao C., Li H., Wei Y. EV-A71 mechanism of entry: Receptors/co-receptors, related pathways and inhibitors. Viruses. 2023;15:785. doi: 10.3390/v15030785.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15030785</ArticleId><ArticleId IdType="pmc">PMC10051052</ArticleId><ArticleId IdType="pubmed">36992493</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B. Universal PCR primers are critical for direct sequencing-based enterovirus genotyping. J. Clin. Microbiol. 2017;55:339–340. doi: 10.1128/JCM.01801-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01801-16</ArticleId><ArticleId IdType="pmc">PMC5228251</ArticleId><ArticleId IdType="pubmed">28031445</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B.M., Mulkey S.B., Campos J.M., DeBiasi R.L. Laboratory diagnosis of CNS infections in children due to emerging and re-emerging neurotropic viruses. Pediatr. Res. 2024;95:543–550. doi: 10.1038/s41390-023-02930-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41390-023-02930-6</ArticleId><ArticleId IdType="pubmed">38042947</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn J.J. Enteroviruses and parechoviruses. Microbiol. Spectr. 2016;4:3. doi: 10.1128/microbiolspec.DMIH2-0006-2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/microbiolspec.DMIH2-0006-2015</ArticleId><ArticleId IdType="pubmed">27337462</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinobe R., Wiyatno A., Artika I.M., Safari D. Insight into the enterovirus A71: A review. Rev. Med. Virol. 2022;32:e2361. doi: 10.1002/rmv.2361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2361</ArticleId><ArticleId IdType="pubmed">35510476</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing J., Wang K., Wang G., Li N., Zhang Y. Recent advances in enterovirus A71 pathogenesis: A focus on fatal human enterovirus A71 infection. Arch. Virol. 2022;167:2483–2501. doi: 10.1007/s00705-022-05606-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-022-05606-4</ArticleId><ArticleId IdType="pubmed">36171507</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi K., Koike S. Cellular receptors for enterovirus A71. J. Biomed. Sci. 2020;27:23. doi: 10.1186/s12929-020-0615-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-020-0615-9</ArticleId><ArticleId IdType="pmc">PMC6954530</ArticleId><ArticleId IdType="pubmed">31924205</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee T.C., Guo H.R., Su H.J., Yang Y.C., Chang H.L., Chen K.T. Diseases caused by enterovirus 71 infection. Pediatr. Infect. Dis. J. 2009;28:904–910. doi: 10.1097/INF.0b013e3181a41d63.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0b013e3181a41d63</ArticleId><ArticleId IdType="pubmed">20118685</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooi M.H., Wong S.C., Lewthwaite P., Cardosa M.J., Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 2010;9:1097–1105. doi: 10.1016/S1474-4422(10)70209-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70209-X</ArticleId><ArticleId IdType="pubmed">20965438</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng K.F., Chen L.L., Huang P.N., Shih S.R. Neural pathogenesis of enterovirus 71 infection. Microbes Infect. 2010;12:505–510. doi: 10.1016/j.micinf.2010.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2010.03.006</ArticleId><ArticleId IdType="pubmed">20348010</ArticleId></ArticleIdList></Reference><Reference><Citation>Podduturi S., Vemula D., Singothu S., Bhandari V. In-silico investigation of E8 surface protein of the monkeypox virus to identify potential therapeutic agents. J. Biomol. Struct. Dyn. 2023:1–14. doi: 10.1080/07391102.2023.2245041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2023.2245041</ArticleId><ArticleId IdType="pubmed">37555596</ArticleId></ArticleIdList></Reference><Reference><Citation>Samantaray M., Pattabiraman R., Murthy T.P.K., Ramaswamy A., Murahari M., Krishna S., Kumar S.B. Structure-based virtual screening of natural compounds against wild and mutant (R1155K, A1156T and D1168A) NS3-4A protease of hepatitis C virus. J. Biomol. Struct. Dyn. 2023:1–18. doi: 10.1080/07391102.2023.2246583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2023.2246583</ArticleId><ArticleId IdType="pubmed">37646701</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E.M., Titus S.A., Xu M., Tang H., Zheng W. High-throughput Zika viral titer assay for rapid screening of antiviral drugs. Assay. Drug Dev. Technol. 2019;17:128–139. doi: 10.1089/adt.2018.881.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/adt.2018.881</ArticleId><ArticleId IdType="pmc">PMC6479255</ArticleId><ArticleId IdType="pubmed">30958701</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabie A.M. Teriflunomide: A possible effective drug for the comprehensive treatment of COVID-19. Curr. Res. Pharmacol. Drug Discov. 2021;2:100055. doi: 10.1016/j.crphar.2021.100055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.crphar.2021.100055</ArticleId><ArticleId IdType="pmc">PMC8433057</ArticleId><ArticleId IdType="pubmed">34870153</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabie A.M. Potent inhibitory activities of the adenosine analogue cordycepin on SARS-CoV-2 replication. ACS Omega. 2022;7:2960–2969. doi: 10.1021/acsomega.1c05998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsomega.1c05998</ArticleId><ArticleId IdType="pmc">PMC8767658</ArticleId><ArticleId IdType="pubmed">35071937</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Xu Z., Liang J., Xu T., Zou W., Zhu L., Wu Y., Dong C., Lan K., Wu S., et al. Rational design and optimization of acylthioureas as novel potent influenza virus non-nucleoside polymerase inhibitors. Eur. J. Med. Chem. 2023;259:115678. doi: 10.1016/j.ejmech.2023.115678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2023.115678</ArticleId><ArticleId IdType="pubmed">37531746</ArticleId></ArticleIdList></Reference><Reference><Citation>Okafor S.N., Meyer A., Gadsden J., Ahmed F., Guzmán L., Ahmed H., Romero J.A.F., Angsantikul P. Drug reprofiling to identify potential HIV-1 protease inhibitors. Molecules. 2023;28:6330. doi: 10.3390/molecules28176330.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules28176330</ArticleId><ArticleId IdType="pmc">PMC10488881</ArticleId><ArticleId IdType="pubmed">37687159</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman N.S., Hulswit R.J.G., Westover J.L.B., Stass R., Paesen G.C., Binshtein E., Reidy J.X., Engdahl T.B., Handal L.S., Flores A., et al. Multifunctional human monoclonal antibody combination mediates protection against Rift Valley fever virus at low doses. Nat. Commun. 2023;14:5650. doi: 10.1038/s41467-023-41171-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-41171-3</ArticleId><ArticleId IdType="pmc">PMC10499838</ArticleId><ArticleId IdType="pubmed">37704627</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowden-Reid E., Ledger S., Zhang Y., Di Giallonardo F., Aggarwal A., Stella A.O., Akerman A., Milogiannakis V., Walker G., Rawlinson W., et al. Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2. Antiviral. Res. 2023;217:105677. doi: 10.1016/j.antiviral.2023.105677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2023.105677</ArticleId><ArticleId IdType="pubmed">37478918</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N., Jiang D., Shao B., Bai T., Chen J., Liu Y., Zhang Z., Zhou Y., Wang X., Zhu Z. Anti-BVDV activity of traditional Chinese medicine monomers targeting NS5B (RNA-dependent RNA polymerase) in vitro and in vivo. Molecules. 2023;28:3413. doi: 10.3390/molecules28083413.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules28083413</ArticleId><ArticleId IdType="pmc">PMC10145726</ArticleId><ArticleId IdType="pubmed">37110647</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M.L., Lee Y.P., Wang Y.F., Lei H.Y., Liu C.C., Wang S.M., Su I.J., Wang J.R., Yeh T.M., Chen S.H., et al. Type I interferons protect mice against enterovirus 71 infection. J. Gen. Virol. 2005;86:3263–3269. doi: 10.1099/vir.0.81195-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.81195-0</ArticleId><ArticleId IdType="pubmed">16298971</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi L., He Y., Chen Y., Kung H.F., He M.L. Potent inhibition of human enterovirus 71 replication by type I interferon subtypes. Antivir. Ther. 2011;16:51–58. doi: 10.3851/IMP1720.</Citation><ArticleIdList><ArticleId IdType="doi">10.3851/IMP1720</ArticleId><ArticleId IdType="pubmed">21311108</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X., Zhang X., Wang F., Wei H., Ma H., Sui M., Lu J., Wang H., Dumler J.S., Sheng G., et al. Clinical efficacy of therapy with recombinant human interferon α1b in hand, foot, and mouth disease with enterovirus 71 infection. PLoS ONE. 2016;11:e0148907. doi: 10.1371/journal.pone.0148907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0148907</ArticleId><ArticleId IdType="pmc">PMC4755579</ArticleId><ArticleId IdType="pubmed">26882102</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S.M. Milrinone in enterovirus 71 brain stem encephalitis. Front. Pharmacol. 2016;7:82. doi: 10.3389/fphar.2016.00082.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2016.00082</ArticleId><ArticleId IdType="pmc">PMC4809901</ArticleId><ArticleId IdType="pubmed">27065870</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K.Y. Enterovirus 71 infection and neurological complications. Korean J. Pediatr. 2016;59:395–401. doi: 10.3345/kjp.2016.59.10.395.</Citation><ArticleIdList><ArticleId IdType="doi">10.3345/kjp.2016.59.10.395</ArticleId><ArticleId IdType="pmc">PMC5099286</ArticleId><ArticleId IdType="pubmed">27826325</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.Y., Wang H.C., Wang K.T., Weng S.C., Chang W.H., Shih D.Y., Lo C.F., Wang D.Y. Neutralization of five subgenotypes of enterovirus 71 by Taiwanese human plasma and Taiwanese plasma derived intravenous immunoglobulin. Biologicals. 2013;41:154–157. doi: 10.1016/j.biologicals.2013.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biologicals.2013.02.002</ArticleId><ArticleId IdType="pubmed">23515089</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiao W., Tan S.R., Huang Y.F., Mu L.H., Yang Y., Wang Y., Wu X.E. The effectiveness of different doses of intravenous immunoglobulin on severe hand, foot and mouth disease: A meta-analysis. Med. Princ. Pract. 2019;28:256–263. doi: 10.1159/000496926.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000496926</ArticleId><ArticleId IdType="pmc">PMC6597916</ArticleId><ArticleId IdType="pubmed">30646003</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H., Li L. Clinical efficacy of early administration of human immunoglobulin on children with severe hand-foot-mouth disease. J. Coll. Physicians Surg. Pak. 2023;33:234–236. doi: 10.29271/jcpsp.2023.02.234.</Citation><ArticleIdList><ArticleId IdType="doi">10.29271/jcpsp.2023.02.234</ArticleId><ArticleId IdType="pubmed">36797638</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G., Zhou F., Gu B., Ding C., Feng D., Xie F., Wang J., Zhang C., Cao Q., Deng Y., et al. In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection. Arch. Virol. 2012;157:669–679. doi: 10.1007/s00705-011-1222-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-011-1222-6</ArticleId><ArticleId IdType="pubmed">22245989</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y.R., Chang C.M., Yeh Y.C., Huang C.F., Lin F.M., Huang J.T., Hsieh C.C., Wang J.R., Liu H.S. Honeysuckle aqueous extracts induced let-7a suppress EV71 replication and pathogenesis in vitro and in vivo and is predicted to inhibit SARS-CoV-2. Viruses. 2021;13:308. doi: 10.3390/v13020308.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13020308</ArticleId><ArticleId IdType="pmc">PMC7920029</ArticleId><ArticleId IdType="pubmed">33669264</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Wang P., Du H., Li N., Jing T., Zhang R., Qi W., Hu Y., Liu T., Zhang L., et al. Prediction of the active components and mechanism of forsythia suspensa leaf against respiratory syncytial virus based on network pharmacology. Evid. Based Complement. Alternat. Med. 2022;2022:5643345. doi: 10.1155/2022/5643345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/5643345</ArticleId><ArticleId IdType="pmc">PMC9328944</ArticleId><ArticleId IdType="pubmed">35911158</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Zhang G., Ling J. Medicinal fungi with antiviral effect. Molecules. 2022;27:4457. doi: 10.3390/molecules27144457.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27144457</ArticleId><ArticleId IdType="pmc">PMC9322162</ArticleId><ArticleId IdType="pubmed">35889330</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien M., Anderson T.K., Jockusch S., Tao C., Li X., Kumar S., Russo J.J., Kirchdoerfer R.N., Ju J. Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase, a key drug target for COVID-19. J. Proteome Res. 2020;19:4690–4697. doi: 10.1021/acs.jproteome.0c00392.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.0c00392</ArticleId><ArticleId IdType="pmc">PMC7640960</ArticleId><ArticleId IdType="pubmed">32692185</ArticleId></ArticleIdList></Reference><Reference><Citation>Radhi M., Ashraf S., Lawrence S., Tranholm A.A., Wellham P.A.D., Hafeez A., Khamis A.S., Thomas R., McWilliams D., de Moor C.H. A systematic review of the biological effects of cordycepin. Molecules. 2021;26:5886. doi: 10.3390/molecules26195886.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26195886</ArticleId><ArticleId IdType="pmc">PMC8510467</ArticleId><ArticleId IdType="pubmed">34641429</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuli H.S., Sharma A.K., Sandhu S.S., Kashyap D. Cordycepin: A bioactive metabolite with therapeutic potential. Life Sci. 2013;93:863–869. doi: 10.1016/j.lfs.2013.09.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2013.09.030</ArticleId><ArticleId IdType="pubmed">24121015</ArticleId></ArticleIdList></Reference><Reference><Citation>Panya A., Songprakhon P., Panwong S., Jantakee K., Kaewkod T., Tragoolpua Y., Sawasdee N., Lee V.S., Nimmanpipug P., Yenchitsomanus P.T. Cordycepin inhibits virus replication in Dengue virus-infected Vero cells. Molecules. 2021;26:3118. doi: 10.3390/molecules26113118.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26113118</ArticleId><ArticleId IdType="pmc">PMC8197141</ArticleId><ArticleId IdType="pubmed">34071102</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu E., Son M., Lee M., Lee K., Cho J.Y., Cho S., Lee S.K., Lee Y.M., Cho H., Sung G.H., et al. Cordycepin is a novel chemical suppressor of Epstein-Barr virus replication. Oncoscience. 2014;1:866–881. doi: 10.18632/oncoscience.110.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncoscience.110</ArticleId><ArticleId IdType="pmc">PMC4303894</ArticleId><ArticleId IdType="pubmed">25621301</ArticleId></ArticleIdList></Reference><Reference><Citation>Nair C.N., Panicali D.L. Polyadenylate sequences of human rhinovirus and poliovirus RNA and cordycepin sensitivity of virus replication. J. Virol. 1976;20:170–176. doi: 10.1128/jvi.20.1.170-176.1976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.20.1.170-176.1976</ArticleId><ArticleId IdType="pmc">PMC354977</ArticleId><ArticleId IdType="pubmed">185411</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma A.K. Cordycepin: A bioactive metabolite of Cordyceps militaris and polyadenylation inhibitor with therapeutic potential against COVID-19. J. Biomol. Struct. Dyn. 2022;40:3745–3752. doi: 10.1080/07391102.2020.1850352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2020.1850352</ArticleId><ArticleId IdType="pmc">PMC7754931</ArticleId><ArticleId IdType="pubmed">33225826</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvala H., Simmonds P. Human parechoviruses: Biology, epidemiology and clinical significance. J. Clin. Virol. 2009;45:1–9. doi: 10.1016/j.jcv.2009.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2009.03.009</ArticleId><ArticleId IdType="pubmed">19372062</ArticleId></ArticleIdList></Reference><Reference><Citation>Baer A., Kehn-Hall K. Viral concentration determination through plaque assays: Using traditional and novel overlay systems. J. Vis. Exp. 2014;93:e52065. doi: 10.3791/52065.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/52065</ArticleId><ArticleId IdType="pmc">PMC4255882</ArticleId><ArticleId IdType="pubmed">25407402</ArticleId></ArticleIdList></Reference><Reference><Citation>Asghar N., Lee Y.P., Nilsson E., Lindqvist R., Melik W., Kroger A., Overby A.K., Johansson M. The role of the poly(A) tract in the replication and virulence of tick-borne encephalitis virus. Sci. Rep. 2016;6:39265. doi: 10.1038/srep39265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep39265</ArticleId><ArticleId IdType="pmc">PMC5159820</ArticleId><ArticleId IdType="pubmed">27982069</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei C., Yang J., Hu J., Sun X. On the calculation of TCID(50) for quantitation of virus infectivity. Virol. Sin. 2021;36:141–144. doi: 10.1007/s12250-020-00230-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-020-00230-5</ArticleId><ArticleId IdType="pmc">PMC7973348</ArticleId><ArticleId IdType="pubmed">32458296</ArticleId></ArticleIdList></Reference><Reference><Citation>Das G., Shin H.S., Leyva-Gómez G., Prado-Audelo M.L.D., Cortes H., Singh Y.D., Panda M.K., Mishra A.P., Nigam M., Saklani S., et al. Cordyceps spp.: A review on its immune-stimulatory and other biological potentials. Front. Pharmacol. 2020;11:602364. doi: 10.3389/fphar.2020.602364.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.602364</ArticleId><ArticleId IdType="pmc">PMC7898063</ArticleId><ArticleId IdType="pubmed">33628175</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabie A.M., Abdalla M. Forodesine and riboprine exhibit strong anti-SARS-CoV-2 repurposing potential: In silico and in vitro studies. ACS Bio Med. Chem. Au. 2022;2:565–585. doi: 10.1021/acsbiomedchemau.2c00039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsbiomedchemau.2c00039</ArticleId><ArticleId IdType="pmc">PMC9631343</ArticleId><ArticleId IdType="pubmed">37582236</ArticleId></ArticleIdList></Reference><Reference><Citation>Eltayb W.A., Abdalla M., Rabie A.M. Novel investigational anti-SARS-CoV-2 agent ensitrelvir “S-217622”: A very promising potential universal broad-spectrum antiviral at the therapeutic frontline of coronavirus species. ACS Omega. 2023;8:5234–5246. doi: 10.1021/acsomega.2c03881.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsomega.2c03881</ArticleId><ArticleId IdType="pmc">PMC9897045</ArticleId><ArticleId IdType="pubmed">36798145</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabie A.M. Efficacious preclinical repurposing of the nucleoside analogue didanosine against COVID-19 polymerase and exonuclease. ACS Omega. 2022;7:21385–21396. doi: 10.1021/acsomega.1c07095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsomega.1c07095</ArticleId><ArticleId IdType="pmc">PMC9244909</ArticleId><ArticleId IdType="pubmed">35785294</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J., Li Y., Wang Y., Liu Y., Liu Y., Wang X. Comparison of anti-HBV regimen with or without adefovir on hepatocellular carcinoma development of chronic hepatitis B patients with compensated cirrhosis: A retrospective cohort study. Infect. Agent. Cancer. 2018;13:17. doi: 10.1186/s13027-018-0189-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13027-018-0189-2</ArticleId><ArticleId IdType="pmc">PMC5963167</ArticleId><ArticleId IdType="pubmed">29796061</ArticleId></ArticleIdList></Reference><Reference><Citation>Borea P.A., Gessi S., Merighi S., Vincenzi F., Varani K. Pharmacology of adenosine receptors: The state of the art. Physiol. Rev. 2018;98:1591–1625. doi: 10.1152/physrev.00049.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00049.2017</ArticleId><ArticleId IdType="pubmed">29848236</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Z., Lee C.I., Shah V.K., Oh E.H., Han J.Y., Bae J.R., Lee K., Chong M.S., Hong J.T., Oh K.W. Cordycepin increases nonrapid eye movement sleep via adenosine receptors in rats. Evid. Based Complement. Alternat. Med. 2013;2013:840134. doi: 10.1155/2013/840134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/840134</ArticleId><ArticleId IdType="pmc">PMC3655593</ArticleId><ArticleId IdType="pubmed">23710239</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao H.L., Liu Z.J., Chang Z. Cordycepin induces apoptosis in human bladder cancer cells via activation of A3 adenosine receptors. Tumour. Biol. 2017;39:1010428317706915. doi: 10.1177/1010428317706915.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1010428317706915</ArticleId><ArticleId IdType="pubmed">28714368</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishat S., Shabir H., Azmi A.S., Ansari H.R. A(3) adenosine receptor: A plausible therapeutic target for cardio-protection in diabetes. Recent Pat. Cardiovasc. Drug Discov. 2012;7:59–70. doi: 10.2174/157489012799362421.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/157489012799362421</ArticleId><ArticleId IdType="pubmed">22300387</ArticleId></ArticleIdList></Reference><Reference><Citation>Kletzien R.F. Nucleocytoplasmic transport of RNA. The effect of 3′-deoxyadenosine triphosphate on RNA release from isolated nuclei. Biochem. J. 1980;192:753–759. doi: 10.1042/bj1920753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bj1920753</ArticleId><ArticleId IdType="pmc">PMC1162393</ArticleId><ArticleId IdType="pubmed">6165357</ArticleId></ArticleIdList></Reference><Reference><Citation>Vignuzzi M., Stone J.K., Arnold J.J., Cameron C.E., Andino R. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature. 2006;439:344–348. doi: 10.1038/nature04388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature04388</ArticleId><ArticleId IdType="pmc">PMC1569948</ArticleId><ArticleId IdType="pubmed">16327776</ArticleId></ArticleIdList></Reference><Reference><Citation>You L., Chen J., Liu W., Xiang Q., Luo Z., Wang W., Xu W., Wu K., Zhang Q., Liu Y., et al. Enterovirus 71 induces neural cell apoptosis and autophagy through promoting ACOX1 downregulation and ROS generation. Virulence. 2020;11:537–553. doi: 10.1080/21505594.2020.1766790.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21505594.2020.1766790</ArticleId><ArticleId IdType="pmc">PMC7250321</ArticleId><ArticleId IdType="pubmed">32434419</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y.Y., Chen C.H., Lin W.C., Tung C.W., Chen Y.C., Yang S.H., Huang B.M., Chen R.J. The role of autophagy in anti-cancer and health promoting effects of cordycepin. Molecules. 2021;26:4954. doi: 10.3390/molecules26164954.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26164954</ArticleId><ArticleId IdType="pmc">PMC8400201</ArticleId><ArticleId IdType="pubmed">34443541</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng B., Zhou X., Tian L., Wang J., Zhang W. IFN-β1b induces OAS3 to inhibit EV71 via IFN-β1b/JAK/STAT1 pathway. Virol. Sin. 2022;37:676–684. doi: 10.1016/j.virs.2022.07.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virs.2022.07.013</ArticleId><ArticleId IdType="pmc">PMC9583119</ArticleId><ArticleId IdType="pubmed">35934228</ArticleId></ArticleIdList></Reference><Reference><Citation>Doetsch P.W., Suhadolnik R.J., Sawada Y., Mosca J.D., Flick M.B., Reichenbach N.L., Dang A.Q., Wu J.M., Charubala R., Pfleiderer W., et al. Core (2′-5′)oligoadenylate and the cordycepin analog: Inhibitors of Epstein--Barr virus-induced transformation of human lymphocytes in the absence of interferon. Proc. Natl. Acad. Sci. USA. 1981;78:6699–6703. doi: 10.1073/pnas.78.11.6699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.78.11.6699</ArticleId><ArticleId IdType="pmc">PMC349117</ArticleId><ArticleId IdType="pubmed">6171822</ArticleId></ArticleIdList></Reference><Reference><Citation>Black P.L., Henderson E.E., Pfleiderer W., Charubala R., Suhadolnik R.J. 2′,5′-Oligoadenylate trimer core and the cordycepin analog augment the tumoricidal activity of human natural killer cells. J. Immunol. 1984;133:2773–2777. doi: 10.4049/jimmunol.133.5.2773.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.133.5.2773</ArticleId><ArticleId IdType="pubmed">6332860</ArticleId></ArticleIdList></Reference><Reference><Citation>Panicali D.L., Nair C.N. Effect of cordycepin triphosphate on in vitro RNA synthesis by picornavirus polymerase complexes. J. Virol. 1978;25:124–128. doi: 10.1128/jvi.25.1.124-128.1978.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.25.1.124-128.1978</ArticleId><ArticleId IdType="pmc">PMC353908</ArticleId><ArticleId IdType="pubmed">202731</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson L.S., Ting R.C., Gallo R.C., Wu A.M. Effect of cordycepin on the replication of type-c RNA tumor viruses. Int. J. Cancer. 1975;15:451–456. doi: 10.1002/ijc.2910150311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.2910150311</ArticleId><ArticleId IdType="pubmed">166934</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>